Nashville Biosciences LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center, and global DNA sequencing giant Illumina Inc.
In a report released today, David Amsellem from Piper Sandler maintained a Buy rating on Amneal Pharmaceuticals (AMRX – Research Report), with ...
Frank Rimerman Advisors LLC slashed its Amgen holdings by 66.2% last quarter, parting with 9,031 shares and retaining only ...
DelveInsight's "DARZALEX Market Size, Forecast, and Market Insight Report" highlights the details around DARZALEX, a human ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
DelveInsight's Molecular Glues Market Insights report includes a comprehensive understanding of current treatment practices, ...
Impact Capital Partners LLC recently injected $234,000 into Amgen Inc., acquiring 898 shares in the medical giant. This move ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...
Most organizations have some type of multifunctional committee set up to evaluate generative AI applications. Those ...
Most organizations have some type of multi-functional committee set up to evaluate generative AI applications. Those ...
Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback